Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

被引：0

作者：

M. Lefort

S. Sharmin

J. B. Andersen

S. Vukusic

R. Casey

M. Debouverie

G. Edan

J. Ciron

A. Ruet

J. De Sèze

E. Maillart

H. Zephir

P. Labauge

G. Defer

C. Lebrun-Frenay

T. Moreau

E. Berger

P. Clavelou

J. Pelletier

B. Stankoff

O. Gout

E. Thouvenot

O. Heinzlef

A. Al-Khedr

B. Bourre

O. Casez

P. Cabre

A. Montcuquet

A. Wahab

J. P. Camdessanché

A. Maurousset

H. Ben Nasr

K. Hankiewicz

C. Pottier

N. Maubeuge

D. Dimitri-Boulos

C. Nifle

D. A. Laplaud

D. Horakova

E. K. Havrdova

R. Alroughani

G. Izquierdo

S. Eichau

S. Ozakbas

F. Patti

M. Onofrj

A. Lugaresi

M. Terzi

P. Grammond

F. Grand’Maison

机构：

[1] Univ Rennes,Arènes

[2] EHESP, UMR 6051, RSMS (Recherche sur les Services et Management en Santé)

[3] CNRS, U 1309

[4] Inserm,Department of Medicine

[5] Univ Rennes,Melbourne MS Centre, Department of Neurology

[6] CHU Rennes,Department of Neurology

[7] Investigation Clinique de Rennes)],Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro

[8] University of Melbourne,Inflammation

[9] Royal Melbourne Hospital,Centre Des Neurosciences de Lyon, UMR5292

[10] The Danish Multiple Sclerosis Registry,Centre Hospitalier Régional Universitaire de Nancy

[11] Copenhagen University Hospital,Centre Hospitalier Universitaire de Rennes

[12] Hôpital Neurologique Pierre Wertheimer,Centre Hospitalier Universitaire de Toulouse

[13] Hospices Civils de Lyon,Centre Hospitalier Universitaire de Bordeaux

[14] Observatoire Français de La Sclérose en Plaques,Service des maladies inflammatoires du système nerveux – neurologie, centre d’investigation clinique de Strasbourg

[15] INSERM,Assistance Publique Des Hôpitaux de Paris

[16] Université,Centre Hospitalier Universitaire de Lille

[17] Claude Bernard Lyon 1,Centre Hospitalier Universitaire de Montpellier

[18] Faculté de médecine Lyon Est,Centre Hospitalier Universitaire de Caen Normandie

[19] Eugene Devic EDMUS Foundation,Centre Hospitalier Universitaire de Nice

[20] Hôpital Central,Centre Hospitalier Universitaire Dijon Bourgogne

[21] Hôpital Pontchaillou,Centre Hospitalier Régional Universitaire de Besançon

[22] Hôpital Purpan,Service de Neurologie

[23] CRC-SEP,Assistance Publique Des Hôpitaux de Paris

[24] Hôpital Pellegrin,Centre Hospitalier Universitaire de Martinique

[25] Hôpitaux Universitaire de Strasbourg,Centre Hospitalier Universitaire Limoges

[26] Hôpital de Hautepierre,Assistance Publique Des Hôpitaux de Paris

[27] Hôpital de La Pitié-Salpêtrière,Centre Hospitalier Universitaire de Poitiers

[28] Hôpital Salengro,Assistance Publique Des Hôpitaux de Paris

[29] Hôpital Gui de Chauliac,Centre Hospitalier de Versailles

[30] Hôpital Côte de Nacre,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[31] UR2CA-URRIS,Division of Neurology, Department of Medicine

[32] ,GF Ingrassia Department

[33] Université Nice Côte d’Azur,Department of Neuroscience, Imaging, and Clinical Sciences

[34] Hôpital,Dipartimento Di Scienze Biomediche E Neuromotorie

[35] Hôpital François Mitterrand,Medical Faculty

[36] Maladies Inflammatoires du Système Nerveux Et Neurologie Générale,Nehme and Therese Tohme Multiple Sclerosis Center

[37] Hôpital Jean Minjoz,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[38] Centre Hospitalier Universitaire de Clermont-Ferrand,School of Medicine and Public Health

[39] Hôpital Gabriel-Montpied,Department of Neurology

[40] Aix Marseille Univ,Department of Neuroscience

[41] APHM,Department of Medicine and Surgery

[42] Hôpital de La Timone,Department of Emergency and General Medicine

[43] Hôpital Saint-Antoine,Department of Neurology, Faculty of Medicine

[44] Fondation Adolphe de Rothschild de L’œil Et du Cerveau,Department of Clinical Epidemiology

[45] Centre Hospitalier Universitaire de Nîmes,Danish Multiple Sclerosis Centre, Department of Neurology

[46] Hôpital Carémeau,Department of Neurology

[47] Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye,Department of Neurology

[48] Centre Hospitalier Universitaire d’Amiens Picardie,Department of Clinical Medicine

[49] Rouen University Hospital,Department of Neurology

[50] Centre Hospitalier Universitaire Grenoble-Alpes,Central Clinical School

来源：

BMC Medical Research Methodology | / 22卷

关键词：

Effectiveness; Multiple sclerosis; Propensity score; Indication bias; Causal contrasts; Censoring; Positivity assumption;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Comparative effectiveness, persistence, and adherence of dimethyl fumarate and fingolimod in patients with multiple sclerosis in Japan: A cohort study
Shimazaki, Sho
Fukasawa, Toshiki
Kondo, Takayuki
Takeuchi, Masato
Okura, Takayuki
Takahashi, Ryosuke
Kawakami, Koji
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2025, 94
[42] Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients.
Moiola, L.
Esposito, F.
Di Cristinzi, M.
Ferre', L.
Sferruzza, G.
Romeo, M.
Radaelli, M.
Sangalli, F.
Robotti, M.
Dallacosta, G.
Colombo, B.
Boneschi, F. Martinelli
Rocca, M. A.
Signori, A.
Martinelli, V.
Filippi, M.
Sormani, M.
Comi, G.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 86 - 87
[43] Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas
Sharmin, Sifat
Roos, Izanne
Freedman, Mark S.
Atkins, Harold
Burman, Joachim
Massey, Jennifer
Sutton, Ian
Withers, Barbara
Macdonell, Richard
Grigg, Andrew
Torkildsen, Oivind
Bo, Lars
Lehmann, Anne Kristine
Havrdova, Eva Kubala
Krasulova, Eva
Trneny, Marek
Kozak, Tomas
van der Walt, Anneke
Butzkueven, Helmut
McCombe, Pamela
Skibina, Olga
Lechner-Scott, Jeannette
Willekens, Barbara
Cartechini, Elisabetta
Ozakbas, Serkan
Alroughani, Raed
Kuhle, Jens
Patti, Francesco
Duquette, Pierre
Lugaresi, Alessandra
Khoury, Samia J.
Slee, Mark
Turkoglu, Recai
Hodgkinson, Suzanne
John, Nevin
Maimone, Davide
Sa, Maria Jose
van Pesch, Vincent
Gerlach, Oliver
Laureys, Guy
Van Hijfte, Liesbeth
Karabudak, Rana
Spitaleri, Daniele
Csepany, Tunde
Gouider, Riadh
Castillo-Trivino, Tamara
Taylor, Bruce
Sharrack, Basil
Snowden, John A.
JAMA NEUROLOGY, 2023, 80 (07) : 702 - 713
[44] Effectiveness and safety of fingolimod in patients with multiple sclerosis switched from natalizumab: results from TRANSITION - a 2-year observational study
Butzkueven, H.
Weller, B.
Giacomini, P. S.
Cohan, S.
Ziemssen, T.
Kropshofer, H.
Bellman, S.
Sienkiewicz, D.
Mbah, A. K.
Geissbuehler, Y.
Tomic, D.
Silva, D.
Trojano, M.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 644 - 645
[45] Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
Brownlee, Wallace J.
Haghikia, Aiden
Hayward, Brooke
Waser, Nathalie
Kayaniyil, Sheena
Khan, Zaeem
Duncan, Julie
Millar, Stefanie
Harty, Gerard T.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 76
[46] Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study
Pape, Katrin
Rolfes, Leoni
Steffen, Falk
Muthuraman, Muthuraman
Korsen, Melanie
Meuth, Sven G. G.
Zipp, Frauke
Bittner, Stefan
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
[47] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Baroncini, Damiano
Ghezzi, Angelo
Annovazzi, Pietro O.
Colombo, Bruno
Martinelli, Vittorio
Minonzio, Giorgio
Moiola, Lucia
Rodegher, Mariaemma
Zaffaroni, Mauro
Comi, Giancarlo
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
[48] Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Meca-Lallana, Jose
Ayuso, Teresa
Martinez-Yelamos, Sergio
Duran, Carmen
Contreras Martin, Yessica
Herrera Navarro, Nicolas
Perez Sempere, Angel
Alvarez-Cermeno, Jose C.
Millan Pascual, Jorge
Meca-Lallana, Virginia
Romero Sevilla, Raul
Ricart, Javier
EUROPEAN NEUROLOGY, 2020, 83 (01) : 25 - 33
[49] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS FINGOLIMOD IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN NORWAY
Toro-Diaz, H.
Cele, C.
Hernandez, L.
Haines, P.
Liu, Y.
Bjornstad, B. M.
Haukaas, F. S.
VALUE IN HEALTH, 2016, 19 (07) : A433 - A433
[50] Comparison of 24 month changes in brain volume among long term users of fingolimod versus glatiramer acetate in patients with multiple sclerosis
Honce, J.
Nair, K.
Hoyt, B.
Sillau, S.
Corboy, J.
Vollmer, T.
Alvarez, E.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 856 - 857

← 1 2 3 4 5 →